Merck KGaA (OTCMKTS:MKGAF) Sees Unusually-High Trading Volume – What’s Next?

Merck KGaA (OTCMKTS:MKGAF) shares saw an uptick in trading volume on Monday. 4,500 shares traded hands during trading, an increase of 623% from the previous session’s volume of 622 shares. The stock last traded at $157.00 and had previously closed at $159.4510.

Merck KGaA Price Performance

The stock has a market capitalization of $19.69 billion, a PE ratio of 23.26 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The stock’s 50 day moving average is $160.88 and its two-hundred day moving average is $150.29.

Hedge Funds Weigh In On Merck KGaA

A number of large investors have recently bought and sold shares of the company. Elefante Mark B acquired a new position in shares of Merck KGaA in the second quarter worth $617,000. Ames National Corp purchased a new stake in shares of Merck KGaA during the second quarter valued at approximately $1,009,000. Notis McConarty Edward acquired a new position in shares of Merck KGaA in the second quarter worth about $1,304,000. North Star Asset Management Inc. bought a new stake in shares of Merck KGaA in the second quarter worth $1,411,000. Finally, Pinnacle Holdings LLC bought a new position in shares of Merck KGaA during the second quarter worth about $1,487,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.

About Merck KGaA

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.

The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.